A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors
Open Access
- 15 July 2001
- Vol. 92 (2) , 414-419
- https://doi.org/10.1002/1097-0142(20010715)92:2<414::aid-cncr1337>3.0.co;2-w
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell linesEuropean Journal Of Cancer, 1999
- Topotecan – A Novel Topoisomerase I Inhibitor: Pharmacology and Clinical ExperienceOncology, 1999
- Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreasEuropean Journal Of Cancer, 1998
- Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study.Journal of Clinical Oncology, 1998
- Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.Journal of Clinical Oncology, 1997
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II studyEuropean Journal Of Cancer, 1996
- Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreasInvestigational New Drugs, 1994
- Activity of Topotecan, a New Topoisomerase I Inhibitor, Against Human Tumor Colony-Forming Units In VitroJNCI Journal of the National Cancer Institute, 1992
- Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activityJournal of Medicinal Chemistry, 1991